Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ENTA
- CUSIP: N/A
- Web: www.enanta.com
Capitalization:- Market Cap: $695.02 million
- Outstanding Shares: 19,083,000
Average Prices:- 50 Day Moving Avg: $34.53
- 200 Day Moving Avg: $32.03
- 52 Week Range: $20.79 - $38.40
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -374.70
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $46.2 million
- Price / Sales: 15.48
- Book Value: $13.96 per share
- Price / Book: 2.68
Profitability:- EBIDTA: ($18,830,000.00)
- Net Margins: -28.68%
- Return on Equity: -4.94%
- Return on Assets: -4.73%
Debt:- Current Ratio: 20.83%
- Quick Ratio: 20.83%
Misc:- Average Volume: 192,940 shs.
- Beta: 0.65
- Short Ratio: 9.28
Frequently Asked Questions for Enanta Pharmaceuticals (NASDAQ:ENTA)
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its earnings results on Monday, May, 8th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.10. The business earned $9 million during the quarter, compared to the consensus estimate of $9.19 million. Enanta Pharmaceuticals had a negative net margin of 28.68% and a negative return on equity of 4.94%. The firm's revenue was down 30.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.09) EPS. View Enanta Pharmaceuticals' Earnings History.
Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?
3 analysts have issued twelve-month target prices for Enanta Pharmaceuticals' stock. Their predictions range from $26.00 to $40.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $31.00 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.
What are analysts saying about Enanta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Enanta Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (7/11/2017)
- 2. J P Morgan Chase & Co analysts commented, "Today after market close, Enanta reported F3Q financial results and provided a pipeline update. While we expect AbbVie’s Viekira Pak to remain a key driver for ENTA shares in 2016, we see the company’s wholly owned assets becoming increasingly important valuation drivers over time." (8/9/2016)
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Foundation Medicine (FMI), Momenta Pharmaceuticals (MNTA), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Genus plc (GNS), Immunomedics (IMMU), Cellectis S.A. (CLLS), Heron Therapeutics (HRTX), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA), CRISPR THERAPTC (CRSP), Mesoblast Limited (MESO), Editas Medicine (EDIT) and Spectrum Pharmaceuticals (SPPI).
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Bruce L.A. Carter Ph.D., Chairman of the Board,Independent Director
- Jay R. Luly Ph.D., President, Chief Executive Officer, Director
- Paul J. Mellett Jr., Chief Financial Officer, Senior Vice President - Finance & Administration
- Yat Sun Sun Or Ph.D., Senior Vice President - Research & Development, Chief Scientific Officer
- Nathaniel S. Gardiner J.D., Senior Vice President, General Counsel
- Nathalie Adda M.D., Senior Vice President and Chief Medical Officer
- Timothy D. Ocain Ph.D., Senior Vice President - New Product Strategy and Development
- Ernst-Gunter Afting M.D., Ph.D.,, Independent Director
- Stephen Buckley Jr., Independent Director
- George S. Golumbeski Ph.D., Independent Director
Who owns Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eqis Capital Management Inc. (0.17%), Adams Diversified Equity Fund Inc. (0.11%), Capstone Asset Management Co. (0.03%), Aperio Group LLC (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Enanta Pharmaceuticals stock include Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?
Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Capstone Asset Management Co., Aperio Group LLC, Louisiana State Employees Retirement System and Eqis Capital Management Inc.. Company insiders that have bought Enanta Pharmaceuticals stock in the last two years include Nathaniel S Gardiner and Terry Vance. View Insider Buying and Selling for Enanta Pharmaceuticals.
How do I buy Enanta Pharmaceuticals stock?
Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $37.47.
MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)Earnings History by Quarter for Enanta Pharmaceuticals (NASDAQ ENTA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q2 2017 | ($0.38) | ($0.28) | $9.19 million | $9.00 million | View | Listen |  |
| 2/8/2017 | Q117 | ($0.18) | ($0.26) | $12.70 million | $11.90 million | View | Listen | |
| 11/21/2016 | Q416 | ($0.11) | ($0.09) | $13.56 million | $12.80 million | View | Listen | |
| 8/8/2016 | Q216 | ($0.09) | ($0.06) | $13.07 million | $14.00 million | View | Listen | |
| 5/9/2016 | Q2 | $0.10 | ($0.09) | $16.80 million | $13.00 million | View | Listen | |
| 2/8/2016 | Q116 | $1.13 | $1.36 | $47.32 million | $48.40 million | View | Listen | |
| 11/23/2015 | Q415 | $0.15 | $0.29 | $16.44 million | $14.40 million | View | Listen | |
| 8/6/2015 | Q315 | $0.19 | $0.13 | $16.18 million | $11.60 million | View | Listen | |
| 5/7/2015 | Q215 | $1.80 | $1.49 | $63.40 million | $57.40 million | View | Listen | |
| 2/5/2015 | Q115 | $3.82 | $2.18 | $86.62 million | $77.50 million | View | N/A | |
| 11/24/2014 | Q414 | ($0.33) | ($0.27) | $3.81 million | $2.60 million | View | Listen | |
| 8/11/2014 | Q314 | $1.65 | $1.81 | $40.83 million | $42.10 million | View | N/A | |
| 5/12/2014 | Q2 | $0.69 | ($0.28) | $1.20 million | $2.20 million | View | Listen | |
| 2/13/2014 | Q114 | ($0.15) | ($0.30) | $1.41 million | $0.89 million | View | N/A | |
| 11/25/2013 | Q4 | ($0.29) | ($0.25) | $1.00 million | $1.30 million | View | Listen | |
| 8/12/2013 | Q213 | ($0.34) | ($0.23) | $0.73 million | $1.60 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)Current Year EPS Consensus Estimate: $0.02 EPS
Next Year EPS Consensus Estimate: $-0.1 EPS
Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Enanta Pharmaceuticals (NASDAQ:ENTA)Insider Ownership Percentage: 9.28%
Institutional Ownership Percentage: 67.33%
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/4/2017 | Yat Sun Or | Insider | Sell | 13,921 | $35.09 | $488,487.89 | |
| 11/29/2016 | Yat Sun Or | Insider | Sell | 13,921 | $31.44 | $437,676.24 | |
| 5/11/2016 | Nathaniel S Gardiner | VP | Buy | 500 | $24.45 | $12,225.00 | |
| 2/12/2016 | Terry Vance | Director | Buy | 2,000 | $27.04 | $54,080.00 | |
| 11/24/2015 | Paul J. Mellett | CFO | Sell | 6,000 | $30.15 | $180,900.00 | |
| 10/15/2015 | Paul J Mellett | CFO | Sell | 7,500 | $40.10 | $300,750.00 | |
| 9/8/2015 | Paul J. Mellett | CFO | Sell | 7,500 | $39.55 | $296,625.00 | |
| 7/13/2015 | Paul J Mellett | CFO | Sell | 7,500 | $46.29 | $347,175.00 | |
| 7/13/2015 | Yat Sun Or | Insider | Sell | 3,750 | $46.29 | $173,587.50 | |
| 6/11/2015 | Paul J Mellett | CFO | Sell | 7,500 | $42.51 | $318,825.00 | |
| 6/11/2015 | Yat Sun Or | Insider | Sell | 3,750 | $42.47 | $159,262.50 | |
| 6/5/2015 | Yat Sun Or | Insider | Sell | 10,750 | $42.02 | $451,715.00 | |
| 5/19/2015 | Paul J Mellett | CFO | Sell | 24,000 | $40.13 | $963,120.00 | |
| 5/11/2015 | Yat Sun Or | Insider | Sell | 8,000 | $36.13 | $289,040.00 | |
| 3/9/2015 | Jay R Luly | CEO | Sell | 15,000 | $33.37 | $500,550.00 | |
| 2/20/2015 | Jay R Luly | CEO | Sell | 15,000 | $35.35 | $530,250.00 | |
| 2/19/2015 | Stephen Jr. Buckley | Director | Buy | 1,000 | $34.00 | $34,000.00 | |
| 2/17/2015 | Nathaniel S Gardiner | VP | Buy | 1,400 | $33.23 | $46,522.00 | |
| 1/16/2015 | Paul J Mellett | CFO | Sell | 4,500 | $49.45 | $222,525.00 | |
| 1/5/2015 | Jay R Luly | CEO | Sell | 15,000 | $50.43 | $756,450.00 | |
| 12/1/2014 | Jay R Luly | CEO | Sell | 15,000 | $45.39 | $680,850.00 | |
| 11/3/2014 | Jay R Luly | CEO | Sell | 15,000 | $42.52 | $637,800.00 | |
| 9/15/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.83 | $398,300.00 | |
| 8/14/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.13 | $391,300.00 | |
| 8/14/2014 | Stephen Jr. Buckley | Director | Buy | 1,000 | $38.95 | $38,950.00 | |
| 7/14/2014 | Paul J Mellett | CFO | Sell | 20,000 | $39.88 | $797,600.00 | |
| 5/1/2014 | Yat Sun Or | Insider | Sell | 5,000 | $36.98 | $184,900.00 | |
| 4/1/2014 | Jay Luly | CEO | Sell | 15,000 | $39.17 | $587,550.00 | |
| 4/1/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.16 | $391,600.00 | |
| 3/24/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.34 | $393,400.00 | |
| 3/4/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 439,334 | $38.82 | $17,054,945.88 | |
| 2/26/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 230,190 | $39.15 | $9,011,938.50 | |
| 2/24/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 60,477 | $39.57 | $2,393,074.89 | |
| 2/14/2014 | Jay Luly | CEO | Sell | 5,800 | $38.10 | $220,980.00 | |
| 1/2/2014 | Jay R Luly | CEO | Sell | 5,800 | $28.05 | $162,690.00 | |
| 12/6/2013 | Marc E Goldberg | Director | Sell | 6,861 | $27.93 | $191,627.73 | |
| 10/14/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 32,301 | $19.84 | $640,851.84 | |
| 10/10/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 36,207 | $21.71 | $786,053.97 | |
| 10/3/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 12,300 | $23.39 | $287,697.00 | |
| 3/26/2013 | Helmut Schuhsler | Director | Buy | 132,949 | $14.00 | $1,861,286.00 | |
| 3/26/2013 | Saints Capital Granite, L.P. | Major Shareholder | Buy | 66,474 | $14.00 | $930,636.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Enanta Pharmaceuticals (NASDAQ:ENTA)
Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Post Quarterly Sales of $8.12 Million
www.americanbankingnews.com - July 16 at 10:48 AM |
| Zacks: Brokerages Anticipate Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Will Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - July 14 at 12:40 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 12 at 12:44 AM |
 | ETFs with exposure to Enanta Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 7:28 PM |
| Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 12:40 PM |
 | Novus Therapeutics Announces Change in Management
www.prnewswire.com - July 11 at 4:18 AM |
 | Enanta To Retain Momentum On The Back Of Upcoming FDA Decision
seekingalpha.com - July 11 at 4:18 AM |
| Zacks Investment Research Upgrades Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to Hold
www.americanbankingnews.com - July 3 at 7:02 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - June 27 at 5:50 PM |
 | Enanta Pharma (ENTA) Presents New Data on EDP-938
www.streetinsider.com - June 27 at 5:17 PM |
| Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at the XIX International Symposium on Respiratory Viral Infections
finance.yahoo.com - June 26 at 9:40 AM |
| Enanta Pharma (ENTA) Announces AbbVie (ABBV) Receives CHMP Positive Opinion for MAVIRET to Treat Chronic Hepatitis C in All Major Genotypes
www.streetinsider.com - June 23 at 10:38 PM |
| Enanta Announces that AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
finance.yahoo.com - June 23 at 5:35 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - June 21 at 6:20 PM |
| Enanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Quarterly Sales of $8.12 Million
www.americanbankingnews.com - June 21 at 8:46 AM |
| Zacks: Analysts Anticipate Enanta Pharmaceuticals, Inc. (ENTA) to Post -$0.49 EPS
www.americanbankingnews.com - June 20 at 12:12 AM |
| ETFs with exposure to Enanta Pharmaceuticals, Inc. : June 13, 2017
finance.yahoo.com - June 13 at 4:44 PM |
| Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ENTA-US : June 13, 2017
finance.yahoo.com - June 13 at 12:00 PM |
| Short Interest in Enanta Pharmaceuticals Inc (ENTA) Drops By 0.6%
www.americanbankingnews.com - June 11 at 7:32 AM |
| Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q2, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 10:48 AM |
| Enanta Pharmaceuticals Inc (ENTA) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $8.12 Million
www.americanbankingnews.com - May 26 at 1:48 PM |
| Zacks: Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce -$0.49 Earnings Per Share
www.americanbankingnews.com - May 24 at 8:08 PM |
| Enanta Pharmaceuticals Inc (ENTA) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 12 at 7:41 PM |
| CORRECTING and REPLACING Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
finance.yahoo.com - May 9 at 8:41 PM |
| Enanta Pharmaceuticals Inc (ENTA) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - May 9 at 4:02 PM |
| Edited Transcript of ENTA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 9 at 8:04 AM |
 | Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call
www.baystreet.ca - May 8 at 4:50 PM |
 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
www.businesswire.com - May 8 at 4:50 PM |
 | Enanta Pharmaceuticals reports 2Q loss
marketbeat.com - May 8 at 4:13 PM |
| Somewhat Positive Media Coverage Very Likely to Impact Enanta Pharmaceuticals (ENTA) Share Price
www.americanbankingnews.com - May 4 at 7:58 PM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $9.24 Million
www.americanbankingnews.com - May 3 at 1:09 PM |
| Zacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 1 at 9:02 PM |
| Favorable News Coverage Very Likely to Impact Enanta Pharmaceuticals (ENTA) Stock Price
www.americanbankingnews.com - April 27 at 9:30 PM |
| Very Positive Media Coverage Extremely Likely to Affect Enanta Pharmaceuticals (ENTA) Share Price
www.americanbankingnews.com - April 23 at 8:00 AM |
| Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates ...
www.businesswire.com - April 21 at 11:59 AM |
| Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients
finance.yahoo.com - April 21 at 11:59 AM |
| Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with …
finance.yahoo.com - April 20 at 5:06 PM |
| AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
finance.yahoo.com - April 20 at 12:30 PM |
| Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
finance.yahoo.com - April 20 at 12:30 PM |
| Enanta Pharma (ENTA) Reports New Preclinical Data on EDP-305 for NASH and PBC at ILC
www.streetinsider.com - April 19 at 4:57 PM |
| Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017
finance.yahoo.com - April 19 at 12:17 PM |
| Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2017
finance.yahoo.com - April 18 at 4:41 PM |
| Enanta Pharmaceuticals (ENTA) Receives Daily News Sentiment Score of 0.14
www.americanbankingnews.com - April 16 at 10:17 AM |
| Brokerages Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - April 10 at 2:30 PM |
| Enanta Pharma (ENTA) Announces Data Presentations at ILC - StreetInsider.com
www.streetinsider.com - April 7 at 9:38 AM |
| Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017
finance.yahoo.com - April 7 at 9:38 AM |
| Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : April 6, 2017
finance.yahoo.com - April 7 at 9:38 AM |
| Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st ... - Business Wire (press release)
www.businesswire.com - March 28 at 4:42 PM |
| Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
finance.yahoo.com - March 27 at 4:46 PM |
Enanta Pharmaceuticals (ENTA) Chart for Saturday, July, 22, 2017
